Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.

PURPOSE To investigate concentrations of growth factors and inflammatory cytokines in eyes with central (CRVO) and branch (BRVO) retinal vein occlusion before and during therapy with bevacizumab and to identify associations with disease activity. METHODS In a prospective clinical trial, 13 eyes of patients with CRVO (n = 5) or BRVO (n = 8) were included. Bevacizumab was administered intravitreously at baseline and months 1 and 2. Retreatments were given at monthly visits if OCT showed edema or when vision loss occurred. Aqueous humor samples were taken each time injections were performed. Follow-up was 15 months. Samples from patients with cataract served as the control. Multiplex bead assays were used for measurement of 28 growth factors and cytokines. RESULTS During therapy with bevacizumab, VEGF levels were reduced to below detection in the first 2 months. Whenever criteria for retreatment were met, VEGF was measurable again. The decrease in VEGF was associated with a decrease in central retinal thickness (CRT) and improvement in visual acuity (VA). Significantly increased concentrations of VEGF, IL-6, IL-8, IP-10, MCP-1, and PDGF-AA were observed in aqueous humor samples of patients with CRVO compared with the control samples. CONCLUSIONS VEGF levels were significantly elevated in patients with CRVO compared with control subjects. Intravitreal injections of bevacizumab resulted in a substantial decrease of VEGF under physiologic levels and remained low under the loading dose of three consecutive monthly retreatments. Macular edema was related to VEGF levels in the aqueous humor.

[1]  U. Schmidt-Erfurth,et al.  Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study , 2008, British Journal of Ophthalmology.

[2]  B. Brown,et al.  Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity , 2007, Clinical ophthalmology.

[3]  A. Zernecke,et al.  Chemokines in vascular remodeling , 2007, Thrombosis and Haemostasis.

[4]  L. Yannuzzi,et al.  REBOUND MACULAR EDEMA FOLLOWING BEVACIZUMAB (AVASTIN) THERAPY FOR RETINAL VENOUS OCCLUSIVE DISEASE , 2007, Retina.

[5]  I. Cree,et al.  Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. , 2006, Experimental eye research.

[6]  R. Bodnar,et al.  IP-10 Blocks Vascular Endothelial Growth Factor-Induced Endothelial Cell Motility and Tube Formation via Inhibition of Calpain , 2006, Circulation research.

[7]  J. Slakter,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study , 2006, Retina.

[8]  Z. Haskova,et al.  Vascular Endothelial Growth Factor-Induced Signaling Pathways in Endothelial Cells That Mediate Overexpression of the Chemokine IFN-γ-Inducible Protein of 10 kDa In Vitro and In Vivo1 , 2006, The Journal of Immunology.

[9]  H. Yamashita,et al.  Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. , 2005, American journal of ophthalmology.

[10]  P. Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[11]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[12]  D. Broide,et al.  Inhibition of airway remodeling in IL-5-deficient mice. , 2004, The Journal of clinical investigation.

[13]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[14]  N. Rao,et al.  Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. , 2003, Investigative ophthalmology & visual science.

[15]  Lois E. H. Smith,et al.  Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. , 2003, The Journal of clinical investigation.

[16]  I. Cree,et al.  Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. , 2002, Archives of ophthalmology.

[17]  N. Aoike,et al.  Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. , 2001, The Journal of allergy and clinical immunology.

[18]  R. Folberg,et al.  Vascular endothelial growth factor upregulation in human central retinal vein occlusion. , 1998, Ophthalmology.

[19]  G. Neufeld,et al.  Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor (*) , 1996, The Journal of Biological Chemistry.

[20]  M. Hangai,et al.  Interleukin-1 gene expression in transient retinal ischemia in the rat. , 1995, Investigative ophthalmology & visual science.

[21]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[22]  D. Wong,et al.  Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. , 1991, Blood.

[23]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[24]  H. Yamashita,et al.  Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion , 2008, Eye.

[25]  Z. Haskova,et al.  Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. , 2006, Journal of immunology.

[26]  A. Feldman,et al.  Interferon γ–Inducible Protein 10 Selectively Inhibits Proliferation and Induces Apoptosis in Endothelial Cells , 2006, Annals of Surgical Oncology.

[27]  H. Yamashita,et al.  Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[28]  J. Mckillop,et al.  Interleukin 8. , 1993, Autoimmunity.

[29]  J. Araujo,et al.  Venous-Occlusive Disease of the Liver. , 1966 .